Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

CON vs ADUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CON Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

CON Overall Winner 6-Pillar Tally: CON 3 – 3 ADUS Matrix Metrics: CON 6 – 4 ADUS

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ADUS carries 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin).

  • Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. CON 43.5/100 HOLD), CON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (17.2% vs. 10.4% operating margin) and revenue trajectory (+8.6% vs. +7.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CON vs ADUS
CON NYSE Head-to-Head Winner
Concentra Group Holdings Parent, Inc.
Services-Specialty Outpatient Facilities, Nec
$41.84
+0.94% 1D
Market Cap $5.2B
TTM Revenue $2.34B
Forward P/E 22.0x
Beta / 30D Vol 0.52β · 38% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 47.0 Flow 69.0 Mom 41.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.0% over 20 days), RSI 56
RSI-14: 55.6 · SMA20: $41.80 · SMA50: $38.66
ADUS NASDAQ
Addus HomeCare Corp.
Services-Home Health Care Services
$122.50
+1.18% 1D
Market Cap $2.3B
TTM Revenue $1.50B
Forward P/E 16.1x
Beta / 30D Vol -0.07β · 21% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 57.0 Fund 52.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.9% over 20 days), RSI 52
RSI-14: 51.6 · SMA20: $123.87 · SMA50: $118.74

6-Pillar Scorecard Institutional Category Breakdown (CON 3 – 3 ADUS)

Columns: Metric · CON · ADUS
1. Valuation Multiples ADUS
Forward P/E 22.0x 16.1x
Trailing P/E 24.5x 20.1x
PEG Ratio N/M 1.05x
EV / Revenue 3.1x 1.5x
2. Growth & Scale CON
Revenue Growth (YoY) +8.6% +7.0%
Earnings Growth (YoY) +36.4% +24.2%
TTM Revenue (USD) $2.34B $1.50B
Market Cap $5.2B $2.3B
3. Profitability & Quality CON
Gross Margin 29.9% 32.3%
Operating Margin 17.2% 10.4%
Net Profit Margin 9.3% 7.4%
Return on Equity (ROE) 47.2% 10.0%
4. Balance Sheet & Cash Flow ADUS
Cash Generation (TTM) $257M $173M EBITDA
Cash Flow Margin 11.0% 11.5% EBITDA Mgn
Net Cash / Leverage $2.04B Net Debt (4.20x D/E) $64.64 Book/Sh · 10.0% ROE
Dividend Yield 0.60% None (0.00%)
5. Options & Positioning CON
Options Structure Phase BREAKOUT UNCLASSIFIED
Current IV / %ile 269.9% (95th %ile) 21.9% (16th %ile)
Put/Call OI Skew 0.79x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat ADUS
OpEx & R&D Intensity 12.7% of Rev ($297M) 21.9% of Rev ($329M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Care Facilities Operator Medical Care Facilities Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CON (6) vs ADUS (4)
Institutional Metric CON ADUS Criterion Row Edge
Market Capitalization
Scale
$5.2B $2.3B Larger Scale CON
Trailing P/E Ratio
Valuation
24.5x 20.1x Lower Multiple ADUS
Forward P/E Ratio
Valuation
22.0x 16.1x Lower Multiple ADUS
Revenue Growth (YoY)
Growth
+8.6% +7.0% Higher Growth CON
Operating Margin (TTM)
Profitability
17.2% 10.4% Higher Margin CON
Net Profit Margin
Profitability
9.3% 7.4% Higher Margin CON
Return on Equity (ROE)
Capital Efficiency
47.2% 10.0% Higher ROE CON
52-Week Range Position
Momentum
91% ($19–$44) 79% ($88–$132) Stronger Trend CON
Beta / 30D Volatility
Risk Regime
0.52β · 38% Vol -0.07β · 21% Vol Lower Realized Risk ADUS
Unified Institutional Score
Composite Signal
43.5 / 100 (HOLD) 59.0 / 100 (HOLD) Higher Composite ADUS
Trailing 12M Revenue (USD)
Operating Scale
$2.34B $1.50B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.9% 32.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.1x EV/Rev 1.05x PEG · 1.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$257M ($2.04B Net Debt (4.20x D/E)) $173M EBITDA ($64.64 Book/Sh · 10.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CON +4.82 pp
CON: +4.68% · ADUS: -0.14%
3M Horizon CON +18.19 pp
CON: +19.58% · ADUS: +1.39%
6M Horizon CON +33.02 pp
CON: +65.24% · ADUS: +32.22%
1Y Horizon CON +105.19 pp
CON: +117.58% · ADUS: +12.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CON vs ADUS. Trailing 12-month operating profitability (CON 17.2% vs ADUS 10.4%) and valuation multiples (CON 22.0x vs ADUS 16.1x Forward P/E) are benchmarked directly in Pillar 4 below.

CON ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.34B
Gross Margin29.9%
Op. Margin17.2%
ROE / Fwd P/E47.2% · 22.0x
ADUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.50B
Gross Margin32.3%
Op. Margin10.4%
ROE / Fwd P/E10.0% · 16.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CON BREAKOUT
99d in phase · OBV NEUTRAL
Current IV 269.9%
IV Percentile 95th %ile
Put/Call OI Skew 0.79x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ADUS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 21.9%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ADUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CON Moat Profile High-Margin Pricing Power Moat
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $5.2B market capitalization and 17.2% operating margin.
OpEx & R&D Reinvestment 12.7% of Rev ($297M)
90D Engineering Disclosures 0 Published
ADUS Moat Profile Cyclical / Execution-Driven Positioning
Medical Care Facilities Operator
Competes within the Medical Care Facilities value chain with $2.3B market capitalization and 10.4% operating margin.
OpEx & R&D Reinvestment 21.9% of Rev ($329M)
90D Engineering Disclosures 0 Published

Investor FAQ CON vs ADUS Key Questions & Quantitative Answers

As of Nov 20, 2026, Concentra Group Holdings Parent, Inc. (CON) is the stronger overall head-to-head candidate over Addus HomeCare Corp. (ADUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). CON carries a Unified Composite Score of 43.5/100 (HOLD) at $41.84 (22.0x Forward P/E, 17.2% operating margin), whereas ADUS carries 59.0/100 (HOLD) at $122.50 (16.1x Forward P/E, 10.4% operating margin). Composite vs. Pillar Nuance: While ADUS currently prints a higher short-term Unified Composite Score (59.0/100 HOLD vs. CON 43.5/100 HOLD), CON captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (17.2% vs. 10.4% operating margin) and revenue trajectory (+8.6% vs. +7.0% YoY).

CON leads the Growth & Scale pillar: CON posts +8.6% YoY revenue growth and +36.4% YoY earnings growth on $2.34B TTM revenue (29.9% gross margin, 17.2% operating margin), compared with ADUS at +7.0% YoY revenue growth and +24.2% YoY earnings growth on $1.50B TTM revenue (32.3% gross margin, 10.4% operating margin). On trailing 12-month operating scale, CON generates $2.34B in USD-normalized revenue versus $1.50B for ADUS. In operating R&D and SG&A reinvestment, CON deploys 12.7% of Rev ($297M) (0 90-day corporate R&D disclosures) versus 21.9% of Rev ($329M) (0 disclosures) for ADUS.

ADUS screens cheaper on headline valuation multiples. CON trades at 22.0x Forward P/E, 24.5x Trailing P/E, N/M PEG, and 3.1x EV/Revenue (11.0% FCF margin), whereas ADUS trades at 16.1x Forward P/E, 20.1x Trailing P/E, 1.05x PEG, and 1.5x EV/Revenue (11.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CON (47.2% ROE) versus ADUS (10.0% ROE) capital efficiency.

In options market volatility and institutional positioning, CON carries 269.9% implied volatility (95th %ile, Extreme (>80th %ile)), a 0.79x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (0.52β · 38% Vol realized risk). By comparison, ADUS carries 21.9% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.07β · 21% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.